PAREXEL International (United Kingdom)
In research, PAREXEL International (United Kingdom) stands highest in Medicine (#12,978 of 17,978 worldwide), Health Sciences (#15,720 of 20,462 worldwide) and Social Sciences (#15,887 of 16,945 worldwide), over all time. Relative to its size it is most specialised in Economics and Econometrics and Economics, Econometrics and Finance — Economics and Econometrics is 14.3× its share of world research.
- World rank, 2022–2025
- #20,322 of 28,054 · #22,892 all time
- Rank in United Kingdom
- #728 of 1,094
- Research works
- 538 ▲ 28% vs 2013–17
- Citations
- 5.7k 10.6 per fractional work
- Top-10% rate
- 6.9% record average 16.5%
- Open access
- 39% world 28%
What is PAREXEL International (United Kingdom) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #12,978 of 17,978 | 11.4% | 178 | |
| Health SciencesDomain | #15,720 of 20,462 | 10.9% | 198 | |
| Social SciencesDomain | #15,887 of 16,945 | 7.4% | 203 | |
| Economics, Econometrics and FinanceField | #3,087 of 3,268 | 7.7% | 163 | |
| Economics and EconometricsSubfield | #2,356 of 2,466 | 7.7% | 160 |
Each strip is that field’s whole ranked pool, with the notch where PAREXEL International (United Kingdom) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does PAREXEL International (United Kingdom) specialise in?
Where its research is concentrated relative to its size: Economics and Econometrics takes 14.3× the share of its output that it takes of world research.
- Economics and EconometricsSubfield · 31.0 works14×
- Economics, Econometrics and FinanceField · 32.8 works11×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 11.2×. Every wedge is a field page.
- Economics, Econometrics and Finance 11.2×
- Immunology and Microbiology 4.3×
- Pharmacology, Toxicology and Pharmaceutics 3.5×
- Mathematics 2.6×
- Medicine 2.0×
- Decision Sciences 1.8×
- Health Professions 1.6×
- Veterinary 1.3×
- Neuroscience 1.0×
- Biochemistry, Genetics and Molecular Biology 0.8×
- Dentistry 0.8×
- Computer Science 0.6×
- Social Sciences 0.3×
- Business, Management and Accounting 0.3×
- Physics and Astronomy 0.3×
- Earth and Planetary Sciences 0.2×
- Chemical Engineering 0.2×
- Environmental Science 0.2×
- Arts and Humanities 0.2×
- Psychology 0.2×
- Engineering 0.2×
- Nursing 0.1×
- Agricultural and Biological Sciences 0.1×
- Materials Science 0.1×
- Chemistry 0.0×
Who are the top researchers at PAREXEL International (United Kingdom)?
Ranked on the composite score, R. Macaulay and K. Rüdell lead among researchers whose main affiliation is PAREXEL International (United Kingdom).
- 1 R. Macaulay United Kingdom · #1,302,451 worldwide 14 citations · 63 works
- 2 K. Rüdell United Kingdom · #1,550,812 worldwide 17 citations · 20 works
Which keywords describe research at PAREXEL International (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Quality of Life, Cost-effectiveness Analysis, Health Utility Measures, Clinical Trials, Lymphoma, Immunotherapy, Ethical Issues and Patient Safety.
- Quality Improvement
- Drug Development
- Biosimilars
- Adverse Drug Reactions
- Adaptive Designs
- Immunogenicity
- Precision Medicine
- Monoclonal Antibodies
- Private R&D
- CAR T Cells
- Stem Cell Regulation
- Direct-to-Consumer Marketing
- Regenerative Medicine
- Cancer Immunotherapy
- Healthcare
- Generic Drugs
- Ethical Issues
- Lymphoma
- Clinical Trials
- Cost-effectiveness Analysis
- Quality of Life
- Health Utility Measures
- Immunotherapy
- Innovation
- Drug Development Costs
- Patient Safety
- Biomarkers
- Global Governance
- Regulatory Challenges
- Innovation Policy
- Bayesian Methods
- Chimeric Antigen Receptor
- R&D Subsidies
- Chemotherapy
- Clinical Outcomes
- Medication Adherence
- False Discovery Rate
- Bioanalytical Methods
- Cognitive Impairment
- Diagnostic Criteria
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Quality of Life21▲ 11×9 topics
- Cost-effectiveness Analysis20▲ 168×1 topic
- Health Utility Measures20▲ 168×1 topic
- Clinical Trials8▲ 8.4×10 topics
- Immunotherapy5▲ 5.5×8 topics
- Lymphoma5▲ 22×2 topics
- Innovation5▲ 3.2×4 topics
- Ethical Issues4▲ 29×4 topics
- Drug Development Costs4▲ 113×1 topic
- Generic Drugs4▲ 113×1 topic
- Patient Safety4▲ 20×3 topics
- Healthcare4▲ 2.6×10 topics
- Biomarkers4▲ 4.0×9 topics
- Cancer Immunotherapy4▲ 18×2 topics
- Global Governance4▲ 12×2 topics
- Regenerative Medicine4▲ 11×2 topics
- Regulatory Challenges4▲ 31×2 topics
- Direct-to-Consumer Marketing4▲ 117×1 topic
- Innovation Policy4▲ 27×2 topics
- Stem Cell Regulation4▲ 117×1 topic
- Bayesian Methods4▲ 52×2 topics
- CAR T Cells4▲ 35×1 topic
- Chimeric Antigen Receptor4▲ 35×1 topic
- Private R&D4▲ 132×1 topic
- R&D Subsidies4▲ 132×1 topic
- Monoclonal Antibodies3▲ 27×2 topics
- Chemotherapy3▲ 3.4×9 topics
- Precision Medicine3▲ 4.5×6 topics
- Clinical Outcomes3▲ 9.5×3 topics
- Immunogenicity3▲ 47×2 topics
- Medication Adherence3▲ 39×2 topics
- Adaptive Designs3▲ 98×1 topic
- False Discovery Rate3▲ 98×1 topic
- Adverse Drug Reactions3▲ 36×2 topics
- Bioanalytical Methods3▲ 97×1 topic
- Biosimilars3▲ 97×1 topic
- Cognitive Impairment3▲ 7.5×4 topics
- Drug Development2▲ 21×2 topics
- Diagnostic Criteria2▲ 7.4×3 topics
- Quality Improvement2▲ 8.0×4 topics
Which research topics does PAREXEL International (United Kingdom) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Biomedical Ethics and Regulation and Innovation Policy and R&D.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 20 works
- 2 Pharmaceutical Economics and Policy Economics and Econometrics 4 works
- 3 Biomedical Ethics and Regulation Physiology 4 works
- 4 Innovation Policy and R&D Economics and Econometrics 4 works
- 5 CAR-T cell therapy research Oncology 4 works
- 6 Biosimilars and Bioanalytical Methods Immunology 3 works
- 7 Statistical Methods in Clinical Trials Statistics and Probability 3 works
- 8 Multiple Sclerosis Research Studies Pathology and Forensic Medicine 2 works
- 9 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 2 works
- 10 Cancer Immunotherapy and Biomarkers Oncology 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has PAREXEL International (United Kingdom)'s research output changed?
Output in 2018–2022 was 28% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Birmingham
- University of Birmingham
- Aston University
- Birmingham City University
- Queen Elizabeth Hospital Birmingham
- Birmingham City Hospital
- Birmingham Children's Hospital
- University Hospitals Birmingham NHS Foundation Trust
- Heartlands Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.